We manufacture and market a large basket of pharmaceutical formulations across chronic and acute therapies, including generics, branded generics, specialty & complex products, over-the-counter (OTC), antiretrovirals (ARV), Active Pharmaceutical Ingredients (API), and intermediates. Our portfolio spans multiple dosage forms such as tablets, capsules, injectables, inhalers, ointments, creams, and liquids. With billions of doses delivered annually across our key therapeutic areas like neuro-psychiatry, cardiology, gastroenterology, anti-infectives diabetology, oncology, ophthalmology, dermatology, urology, nephrology, respiratory, and more, we are helping improve access to medicine globally.
Recent Posts
- Sun Pharma launches its semaglutide injection under the brand names, Noveltreat and Sematrinity in India
- Sun Pharma Announces US FDA Acceptance of Supplemental Biologics License (sBLA) Application for ILUMYA® (tildrakizumab-asmn) for the Treatment of Adults with Active Psoriatic Arthritis
- Sun Pharma Comes on Board as Principal Sponsor and Health Partner of Royal Challengers Bengaluru (RCB) for T20 Season 2026
- Sun Pharma reports Q3FY26 results
- Sun Pharma receives DCGI approval to manufacture and market generic semaglutide injection in India for chronic weight management
Recent Comments